Cytokinetics, Incorporated (CYTK) Earnings Call Transcript & Summary
November 6, 2024
Earnings Call Speaker Segments
Diane Weiser
executiveGood afternoon, and thank you for being with us today. Robert Blum, our President and Chief Executive Officer, is going to kick things off with a look at the quarter and what's happened recently. Fady Malik, EVP of R&D, will share updates on the clinical development program for aficamten. Andrew Callos, EVP and Chief Commercial Officer, will discuss commercial readiness efforts for aficamten. Stuart Kupfer, SVP and Chief Medical Officer, will give updates on omecamtiv mecarbil, CK-586, and our earlier-stage development pipeline. Sung Lee, EVP and Chief Financial Officer, will walk through a financial overview of the third quarter. And last, Robert will go over our corporate development strategies and the milestones we expect ahead. Please be aware that parts of what we discuss next, including answers to your questions, include statements about future events and performance instead of historical facts, and these are forward-looking statements. What actually happens could differ materially from what these forward-looking statements project. More details on factors that could make our actual results differ materially from those in these forward-looking statements can be found in our SEC filings, including our current report on our third quarter 2024 financial results filed on Form 8-K that was furnished to the SEC today. We have no obligation to update any forward-looking statements after this call. And with that, I'll hand the call over to Robert.
Robert Blum
executiveThanks, Diane, and I appreciate everyone being with us today. As we told you only a few weeks back during our Investor and Analyst Day, the third quarter brought substantial advancement throughout our pipeline. Above all else, we finished the rolling submission and handed our new drug application over to the FDA for aficamten. That represents a thrilling landmark for Cytokinetics, and likewise for the physicians and patients involved, and it moves us nearer to the possibility of delivering aficamten to people who suffer from obstructive HCM. It stands as evidence of an enormous amount of effort put in by our colleagues, and for that we are particularly thankful. We have asked for priority review of the submission, though our base case remains standard review. What comes next should be the announcement of filing acceptance along with an assigned PDUFA date. In Q3, we additionally assisted CORXEL, previously known as Ji Xing, with the NDA filing in China for aficamten in obstructive HCM, and we are happy to report today that it was accepted for filing not long ago. In the meantime, our commercial readiness for a possible approval and launch of aficamten inside the United States is ramping up as planned. As Andrew will explain in more detail, we are carrying out prelaunch activities, among them a recently kicked-off HCM disease awareness campaign aimed at health care professionals. On top of that, we chose third-party external partners to assist with education, distribution and patient support, which together create a tailored patient experience. We also fine-tuned sales territory configurations along with sales training and recruiting programs in the United States, and at the same time we brought on our first geographic and functional team leaders in Europe. Throughout the quarter, we kept presenting and publishing further data from SEQUOIA-HCM, which only reinforces the evidence behind its possible next-in-class safety and efficacy profile. As Fady will explain further, those extra analyses demonstrate that aficamten treatment is tied to gains in exercise capacity, gradients, symptoms, biomarkers, cardiac structure and function, plus favorable cardiac remodeling. Taken together, these analyses meaningfully broaden the overall profile of aficamten and support the positioning we anticipate for a next-in-class cardiac myosin inhibitor that we think can grow the category and drive wider adoption. Past aficamten, we got ready to kick off 2 new clinical trials within our emerging specialty cardiology franchise: COMET-HCF, the confirmatory Phase III clinical trial for omecamtiv mecarbil, and AMBER-HFpEF, the Phase II clinical trial for CK-586. As Stuart will describe, omecamtiv mecarbil and CK-586 each present a chance to grow our specialty cardiology franchise by going after underserved populations at opposite ends of the heart failure spectrum — those whose ejection fraction is severely reduced and those whose ejection fraction is supernormal. Last of all, even though our specialty cardiology franchise stays our number one priority, our research into novel muscle-directed therapies has carried on inside our labs in South San Francisco, and our many years of innovation in muscle biology continues with yet another promising drug candidate named CK-089, which is being readied to start a first-in-human study. CK-089 works as a fast skeletal muscle troponin activator, and our belief is that it could hold therapeutic promise for one particular form of muscular dystrophy. You are going to hear additional detail regarding the way we've taken what earlier fast skeletal troponin activators taught us and folded those lessons into the next-stage strategy for CK-089, since clinical development on it is set to kick off shortly, during this fourth quarter. The position Cytokinetics occupies right now reflects deliberate planning, strategic placement, and careful use of capital, and all of that serves the goal of unlocking the complete potential of our muscle biology platform; we aren't a business that merely expects to construct everything around one drug candidate succeeding. What we're doing instead is concentrating on generating momentum throughout our pipeline and preparing for what lies ahead by advancing a portfolio containing several muscle-directed drug candidates, each designed to tackle diseases where unmet need runs high. Through those efforts, our hope is to change patients' lives while also delivering meaningful value back to shareholders in ways that last. Having said that, I'll hand things over to Fady, go ahead.
Fady Malik
executiveAppreciate that, Robert. During Q3, we shared further findings from SEQUOIA-HCM and FOREST-HCM across 3 medical congresses: the European Society of Cardiology Congress, the Hypertrophic Cardiomyopathy Society Scientific Sessions, and the Heart Failure Society of America Annual Scientific Meeting. These pre-specified analyses extend the primary results that were presented and published earlier in the year, allowing a deeper look into aficamten's profile. The breadth and scale of this work is genuinely remarkable — 8 presentations, 5 of them late breakers, along with 5 simultaneous publications in top cardiac journals. Every one of these analyses came in above our best case expectations for aficamten and strengthens our confidence in its opportunity to address a significant unmet need in obstructive HCM. Among the key additional data from SEQUOIA-HCM are findings indicating that aficamten may be linked to favorable cardiac remodeling and improvements across several measures of cardiac structure and function. Taken together, these data indicate that aficamten appears to alter the architecture of the heart and could potentially be disease-modifying — something essential to changing the trajectory of HCM. Other SEQUOIA-HCM analyses presented during the quarter demonstrated that treatment with aficamten improved patients' symptoms, quality of life, and cardiac biomarkers. In addition, a responder analysis showed aficamten was tied to broad clinical efficacy, since the majority of patients receiving aficamten in SEQUOIA-HCM achieved one or more clinically relevant outcome. Among the 4 pre-specified outcomes was a complete hemodynamic response, defined as a resting LVOT gradient below 30 and a Valsalva LVOT gradient below 50, which 2/3 of patients in SEQUOIA-HCM achieved. Complementing these data were findings from an integrated safety analysis drawing on REDWOOD-HCM, SEQUOIA-HCM, and FOREST-HCM, which reinforced aficamten's safety profile. Lastly, an analysis of open-label FOREST-HCM data showed that most patients who attempted withdrawal of standard of care medications at an investigator's discretion succeeded, with some reaching monotherapy — suggesting aficamten has the potential to be tolerated and effective as monotherapy in patients with oHCM. That hypothesis is under further exploration in the MAPLE-HCM trial, which I'll get to shortly. Five of the recent publications were gathered together in the November 5 issue of the Journal of American College of Cardiology — close to an entire issue dedicated to aficamten. As we keep curating the SEQUOIA-HCM data, each new analysis expands on the primary SEQUOIA-HCM results to bolster the effect of aficamten on clinical outcomes, symptom burden, cardiac biomarkers, and cardiac structure and function. Altogether, this large and expanding body of evidence provides a clear picture of aficamten's relevance to clinical practice as a next-in-class cardiac myosin inhibitor and potentially the cardiac myosin inhibitor of choice for physicians and patients alike. All of these clinical work streams also remain supported by our medical affairs organization. Throughout this quarter, members of our field medical organization held discussions with health care professionals—among them numerous HCM KOLs, along with hospital and IDN leadership and those who make formulary decisions—to talk through and raise awareness of what came out of SEQUOIA-HCM. Turning now to the clinical trials program for aficamten that's still underway: we're happy to say that enrollment finished in MAPLE-HCM during Q3. For the remainder of this year, we'll keep running this important trial, and we anticipate reporting results from MAPLE-HCM in the first half of 2025, which comes before the point at which we hope to bring aficamten to market commercially. Should the findings be positive, MAPLE-HCM stands as the first possible label expansion opportunity for aficamten, with data that could supply the rationale for positioning it as first-line therapy within practice guidelines. Also in the quarter, we kept enrolling patients in ACACIA-HCM, the pivotal Phase III clinical trial of aficamten in patients who have symptomatic non-obstructive HCM. More than 90 sites across 13 countries are now activated, which ensures that results from ACACIA-HCM will reflect a broad and diverse study population. Enrollment is moving briskly, and we expect to keep activating new sites and enrolling patients both at existing and new sites through this year and into next year, working toward our goal of finishing enrollment in 2025. In addition, we carried on with CEDAR-HCM, which evaluates a pediatric population of patients with symptomatic oHCM, as well as one more Phase I study of aficamten involving healthy Japanese and Caucasian participants that may help support development of aficamten in Japan. All in all, I take pride in the substantial progress achieved across the clinical development program for aficamten during the third quarter. I'll now hand things over to Andrew.
Andrew Callos
executiveAppreciate that, Fady. During Q3, we kept moving forward with the work needed to get ready commercially for a possible approval and launch of aficamten in the United States. We were glad to roll out HCM Beyond the Heart, which is an unbranded effort to raise disease awareness aimed at health care professionals. That initiative came from market research plus real-world input provided by cardiologists, nurses and patients, and it tells the story of 5 people who live with HCM in order to shed light on the many-sided daily struggle that those with HCM endure; we intend to feature this initiative at the AHA scientific session taking place in Chicago next week, and we are looking to introduce a comparable unbranded awareness effort centered on patients during first quarter 2025. Rolling out HCM Beyond the Heart likewise represented the initial use of our omnichannel digital communication approaches, which has effectively confirmed that our planning investment was worthwhile and laid the groundwork for wider digital engagement coming before and throughout the period of possible approval and launch in 2025. In Q3, we chose outside third-party partners for our tailored patient experience, which we view as a crucial point of differentiation for our possible commercial launch; we additionally achieved meaningful headway in locking down our promotional launch campaign. Beyond that, we moved our sales force preparations ahead, which included completing our customer call list and setting the geographic boundaries for our planned sales territories. We have additionally put together a strong recruiting plan and a training curriculum for roughly 125 to 150 reps that we anticipate adding. Although we don't intend to bring on sales reps until we get nearer to launch next year, we already have hundreds of qualified candidates in our pipeline before we even go out into the marketplace to recruit. On the payer front, we kept up pre-approval information exchange with key payers and made headway building our payer value dossier for payers both in the U.S. and ex-U.S. Our HEOR team was also busy presenting and publishing research that shines a light on the unmet need in HCM, the cost burden tied to current treatment and the possible value of aficamten in HCM. Turning to commercial readiness work in Europe. Our approach is to focus on major markets and to gate hiring and capital deployment in line with regulatory and reimbursement milestones on a country-by-country basis. In Q3, we crafted our distribution model, sharpened regulatory and labeling strategies, set country launch sequencing, engaged with European key opinion leaders and pushed forward development of the HTA dossier while continuing to engage key HTAs for early scientific advice. We also put in place our initial go-to-market plan for Germany, which we expect to be the first country where aficamten is launched in Europe. We now have a head of Europe in place and are recruiting for key country leadership in the U.K. and France as well as functional leadership roles for European operations, once again, in line with gated investment. As we move nearer to the possible approval of launch of aficamten, our commercial readiness efforts keep ramping up. What matters greatly is that the work we are doing right now on aficamten is going to make possible synergies with potential commercial launches later on throughout our specialty cardiology franchise. Resources that are shared, along with systems, commercial infrastructure and the sales organization, are going to help bring about greater efficiencies and effectiveness with every specialty cardiology launch. Having said that, I will now hand the call over to Stuart.
Stuart Kupfer
executiveThank you, Andrew. I'd like to begin by discussing CK-586, which is our next cardiac myosin inhibitor, and it's being developed as a possible therapy for a subset of patients who have heart failure with preserved ejection fraction, or HFpEF, along with hypercontractility. In the quarter, we shared the complete results from the Phase I trial of CK-586 at the American College of Clinical Pharmacology, and those results demonstrated that the drug was both safe and well tolerated. We didn't see any serious adverse events, and no criteria that would stop the study were triggered. The half-life for CK-586 came in at 14 to 17 hours. Dose proportional exposure was shown by CK-586, along with a PK/PD relationship for left ventricular ejection fraction that looked shallow and predictable. When given as the highest single dose of 600 milligrams, the average drop in ejection fraction came in under 5%. Taken together, these findings show pharmacologic characteristics that could support giving a fixed dose once per day. Since the results from this Phase I trial supported moving ahead with Phase II, we initiated start-up work for AMBER-HFpEF, a Phase II clinical trial of CK-586 involving patients who have symptomatic HFpEF with an ejection fraction of at least 60%, and it's intended to assess the safety, tolerability, and pharmacodynamic profile of CK-586 versus placebo. We're happy to report that we remain on track to launch AMBER-HFpEF prior to the end of the year. Now let's turn to omecamtiv mecarbil, our cardiac myosin activator, which is being developed as a possible treatment for a subset of patients who have heart failure with severely reduced ejection fraction. In the quarter, we carried out study start-up work for COMET-HF, the confirmatory Phase III clinical trial that will assess how effective and safe omecamtiv mecarbil is in 1,800 patients who have symptomatic heart failure with severely reduced ejection fraction below 30%. COMET-HF has been designed with pragmatic elements to boost the efficiency of running the study and to lessen the burden on patients. We anticipate launching this trial in the fourth quarter. Heart failure with reduced ejection fraction, or HFrEF, accounts for roughly half of the heart failure population. Looking more closely, estimates indicate a sizable and expanding group of patients with high-risk heart failure and severely reduced ejection fraction below 30%; these patients experience recurrent heart failure events; their use of guideline-directed medical therapy may be limited because of poor tolerability, and they have very elevated NT-proBNP, which is consistent with severe heart failure. Even with the use of SGLT2 inhibitors, a substantial residual risk of cardiovascular events remains in this subset of patients with HFrEF; in GALACTIC-HF, this subset of patients with severely reduced ejection fraction saw a substantially greater treatment benefit from omecamtiv mecarbil. While omecamtiv mecarbil targets patients who have heart failure with severely reduced ejection fraction, CK-586 is intended to address patients with super and normal ejection fraction, at the opposite end of the heart failure spectrum. These patients also have high unmet need, and despite advances in care with SGLT2 inhibitors, they face a poor prognosis after being hospitalized for heart failure. Although the underlying disease processes differ between these two heart failure groups, there's still substantial unmet need for both subgroups of patients, even with guideline-directed medical therapy, and they face a sharply elevated danger of cardiovascular death and hospitalization because of acute decompensated heart failure. Omecamtiv mecarbil along with CK-586 each give us chances to grow our specialty cardiology franchise into these populations sitting at opposite ends of the heart failure spectrum; and now, turning away from our specialty cardiology franchise, as Robert said, we're happy to be rebuilding our neuromuscular pipeline through a new drug candidate that came out of our research, known as CK-089. CK-089 works as a fast skeletal muscle troponin activator, or FSTA, built to boost how skeletal muscle responds to nerve input, lengthening the time before fatigue sets in and raising muscle force and power, with possible therapeutic use for one particular form of muscular dystrophy. With IND-enabling studies now finished, we anticipate launching a first-in-human Phase I trial of CK-089 in healthy subjects shortly. We're eager to reveal further specifics of our plans to revitalize our neuromuscular development work, guided by what we learned previously, very soon. What that amounts to is that before this year ends, we'll have at least one drug candidate sitting in every stage of clinical development, from Phase I through Phase III, which shows how rich our pipeline is in muscle-directed therapies. With that said, I'll hand things over to Sung.
Sung Lee
executiveThanks, Stuart. We're happy to share the results for our third quarter of 2024. Let's begin with the balance sheet. As of the close of the third quarter of 2024, we had roughly $1.3 billion in cash, cash equivalents and investments, versus $1.4 billion at the close of the second quarter of 2024. During the third quarter of 2024, cash, cash equivalents and investments fell by about $81 million. Now to the income statement. Total revenues for the third quarter of 2024 came in at $0.5 million, compared with $0.4 million during the same period in 2023. R&D expenses for the third quarter of 2024 were $84.6 million, versus $82.5 million during the same period in 2023. That increase was mainly the result of higher personnel-related expenses aimed at advancing our pipeline, partly offset by clinical trials that wrapped up in 2023. G&A expenses for the third quarter of 2024 were $56.7 million, versus $40.1 million during the same period in 2023. That increase was mainly the result of investments toward commercial readiness as well as personnel-related expenses. Net loss for the second quarter of 2024 was $160.5 million, or $1.36 per share basic and diluted, versus a net loss of $129.4 million, or $1.35 per share basic and diluted, during the same period in 2023. Now to financial guidance for 2024. We are reiterating every aspect of the guidance we gave previously, which you can find in our press release. As we move toward the end of 2024, our balance sheet continues to be an asset and puts us in a strong position to get ready for the potential launch of aficamten, move forward our earlier and later-stage pipeline, and put money into our proven muscle biology platform. We expect to capture synergies from the commercial and R&D investments, since our potential future medicines and development activities can all take advantage of the infrastructure and capabilities we are building now and in the years ahead. We think these capital allocation priorities can help us become a leader in specialty cardiology with multiple medicines, bringing benefit for patients and sustainable growth for investors. With that, I'll turn things back over to Robert.
Robert Blum
executiveThank you, Sung. The third quarter was certainly defined by significant accomplishments, extending a year that has been characterized by meaningful advancement. Twelve months from now, we anticipate that our organization will appear markedly different, and we are constructing our infrastructure and capabilities so that we can secure our achievements in the years ahead. Toward that goal, throughout the quarter, we continued to bolster our executive leadership team by bringing on Brett Pletcher, who came aboard as EVP, Chief Legal Officer, in August. Brett brings a wealth of experience as an accomplished attorney and industry executive, with deep expertise in building operational reach and capacity and delivering pragmatic legal counsel, having dedicated 17 years to Gilead, 13 of which he served as General Counsel; we consider ourselves lucky to welcome Brett to our team as we anticipate the next significant chapters for Cytokinetics along with greater scope and scale as our corporate development matures. Cytokinetics is well capitalized and well situated for future achievements. As we move toward possible approval and launch of aficamten in the United States, with global launches hopefully to come afterward, we are nearing a critical inflection point for our company. As we anticipate that moment and what lies beyond, we are preparing the foundation for our Vision 2030 and for sustained growth and lasting future achievements as a leading specialty cardiology company. As you have heard, this business remains rooted in aficamten for the possible treatment of HCM, followed by omecamtiv mecarbil for the possible treatment of heart failure with severely reduced ejection fraction and then CK-586 for the possible treatment of heart failure with preserved ejection fraction. This franchise structure is deliberate, with shared characteristics across these patient populations and the prescribers who treat them, including a limited distribution model, few or ineffective available therapies and high unmet patient need. Every one of these factors highlights potential for greater return on investment and gives us the capacity to achieve R&D and commercial synergies. To accomplish these goals, we are dedicated to investing prudently and preserving a strong financial foundation to facilitate both forward motion and velocity. Reflecting on the quarter, I take pride in the enormous progress we have achieved toward realizing our vision. Now I will summarize our forthcoming milestones. For aficamten, we anticipate continuing to advance our go-to-market strategies and to prepare for launching aficamten in the United States in 2025, naturally, subject to FDA approval. We anticipate filing an MAA to the EMA in Q4 2024 and coordinating with CORXEL to support the planned launch of aficamten in China in 2025, pending approval. We anticipate finishing conduct of MAPLE-HCM and sharing results in the first half of 2025. We anticipate continuing enrollment in ACACIA-HCM through 2024 with the objective to complete enrollment in 2025. And we anticipate continuing enrollment in CEDAR-HCM as well as the Phase I study of aficamten in Japanese and Caucasian participants. And for omecamtiv mecarbil, we anticipate starting COMET-HF, the confirmatory Phase III clinical trial in this Q4 2024. Regarding CK-586, our plan is to kick off AMBER-HFpEF, that Phase II clinical trial, during Q4 2024 as well. Turning to earlier-stage clinical work, preclinical work, and research already underway, we anticipate launching clinical development for CK-089 by beginning a Phase I study in healthy volunteers in this same fourth quarter, and we look to carry forward active preclinical development plus research efforts aimed at further muscle biology-focused programs across this year. Operator, at this point, please go ahead and open the line for questions.
Phoebe Tan
analystPhoebe here, filling in for Akash. When we look at the SEQUOIA results, it appears the biggest drops in LVEF occurred among hypercontractile patients whose LVEF was above 75. Suppose you had a mechanism capable of demonstrating gradient relief benefits while leaving LVEF untouched — first, would that even be considered, and would it offer clinical value to individuals with severe hypercontractility? And second, should we still anticipate a pVO2 benefit?
Robert Blum
executiveThanks. Fady, could you please address that?
Fady Malik
executiveAbsolutely. I believe the fundamental idea you raised is that this condition involves excessive contractility. In certain instances, and actually in the majority of cases, it also produces obstruction. An ejection fraction of 80% simply isn't normal. Even among individuals without hypertrophic cardiomyopathy, that figure is not normal; therefore, we believe one goal in managing this illness is to bring contractility down toward more typical levels, allowing tissue remodeling, myofibril disarray, and cardiac wall stresses to start diminishing, while also lowering the gradient. So I'm not sure whether addressing obstruction alone would be enough. You could accomplish that through septal reduction therapy, for example, and that approach does yield meaningful symptom improvement for patients. Yet frequently, as their disease advances, they eventually develop nonobstructive HCM along with other problems. Thus, in my view, merely treating obstruction without also reducing the hypercontractility may not deliver therapeutic value.
Tessa Romero
analystTurning to the Phase III MAPLE-HCM study involving symptomatic oHCM patients, how much confidence do you have that it will succeed? More specifically, might you explain what size of change for aficamten versus metoprolol is required for a significant p-value? Also, what information can you share regarding whether the enrolled patients matched what you had anticipated?
Robert Blum
executiveThose are good questions. Clearly, with the MAPLE-HCM readout coming next year, our view is that this trial will matter greatly when it comes to considering and adopting aficamten, ideally alongside guidelines that are evolving. Moreover, MAPLE-HCM was deliberately built — maybe, in a sense, to speed up something that could otherwise have been a Phase IV trial — and might make label expansion possible. I will turn it over to Fady to address the way we structured the trial and our feelings about those patients who joined.
Fady Malik
executiveYeah. I believe this is a trial that the investigator community has embraced quite enthusiastically, since it addresses a key question for them. As far as getting patients enrolled, I think we've performed strongly in bringing in patients who hit the target, who have meaningful symptoms, who show a meaningful decrease in exercise capacity, and for whom starting therapy with aficamten or metoprolol will let us determine which — what size of benefit each of those treatments provides and how the two stack up against each other. So for a number of reasons, we believe aficamten has already demonstrated benefit on top of beta blockers. And so these are patients who — who were symptomatic, were given beta blockers, didn't respond adequately to that treatment, and afterward responded to aficamten. In SEQUOIA, we had patients taking aficamten, not taking beta blockers. We had beta blocker patients, not receiving any other therapy. And I think that provided us a window into what we expect to observe here, which I think is that the results will align with this trial's hypothesis. I won't really speculate about what counts as meaningful or how large a change we're after; we've powered the trial rather conservatively, looking at a delta-Peak VO2 of about 2 with decent power to detect anything down to roughly 1.5 when it comes to change in Peak VO2, which spans the region where SEQUOIA was positive as well. So I think we have adequate power, and we look forward to the results.
Salim Syed
analystI suppose I have one about MAPLE too. If you do end up achieving the outcomes you're aiming for, can you share your perspective on how those findings would be published and incorporated into treatment guidelines? For instance, how frequently does the committee convene, and when might that take place? Is it possible that it happens before the supplementary approval?
Robert Blum
executiveYeah; clearly, we aren't in a position to promise what other parties will do, but guidelines get refreshed continually and on a regular basis, rather than only annually. And as you've already witnessed during this year, we've pushed hard to make certain that data move rapidly from presentation to publication. I believe we've had a fairly exceptional quantity of presentations and publications this year, which highlights how intently we're collaborating with the academic community to ensure these data receive proper peer review and get published for consideration. So that won't be different next year.
Salim Syed
analystIs it possible for you to complete that before the formal approval happens? My understanding is that publication is the trigger point, right?
Robert Blum
executiveAre you referring to when guidelines get taken into consideration?
Salim Syed
analystYeah, yeah, that's right. Yeah.
Robert Blum
executiveI'd imagine that has a major impact. And getting it published as soon as we can next year is definitely what we're aiming for. I don't think we ought to get ahead of even having the data by making a commitment on whether that would come before a possible approval. But since you know this is what we're focused on, I think you can figure we'll keep pushing very hard.
Nikola Gasic
analystNik Gasic here, filling in for Roanna. Starting with MAPLE, perhaps I can frame it another way. When you think about the afi versus metoprolol results coming next year, what might the Peak VO2 gain from afi in that trial look like compared with what SEQUOIA showed before? And then, if the MAPLE data turn out positive, how do you view the timeline for potential guideline adoption of afi in earlier lines of therapy?
Robert Blum
executiveSeems like we may have just covered that, but perhaps I'll pass it to Fady and check whether he has anything further to add.
Fady Malik
executiveSure. I'll just restate that in SEQUOIA, we saw an improvement of 1.74 mL/kilo/minute among patients who weren't taking beta blockers. That effect was somewhat larger. So we're roughly within that same range for Peak VO2 improvement. Earlier publications on metoprolol in HCM demonstrated that metoprolol fails to raise Peak VO2. So you can infer that if we land in a comparable ballpark, we could potentially observe something along those lines. This trial is smaller than SEQUOIA was; we're treating patients who are a bit less symptomatic, since we aimed to widen the aperture toward naive patients and newer patients; so the precise effect size is somewhat difficult to handicap, though I don't believe the precise effect size is truly what matters. What matters is that aficamten delivers a meaningfully different and superior effect on improving exercise function and symptoms compared with what metoprolol achieves in these patients; so that ought to steer its use in therapy. Regarding the guidelines, I mean, this — we'll present this; we'll get it published, I believe, quite quickly. The guideline committees, they don't make their meeting schedules public, they don't make public their timing for updating guidelines, but they recognize that this field moves fast and that they must be timely and sort of weigh the evidence and revise their guidelines. So I'll leave it there.
Nikola Gasic
analystUnderstood. Then, if I might add, could you share your perspective on what the European launch might look like for afi, assuming it gets approved? And perhaps any lessons you could take from watching the competitor's rollout across Europe?
Robert Blum
executiveAt the moment we're limiting each analyst to a single question, though I'd imagine your question will come up naturally as we work through what appears to be a very lengthy queue of people wanting to ask something. We'll circle back to that. Operator, could we go to the next one, please.
Cameron Bozdog
analystThis is Cameron Bozdog, filling in for Jason. Nice work on the quarter. Now, when it comes to using afi's profile to justify a possible pricing premium, what do you think the key factors would be? Would efficacy matter most, or safety, or the administrative profile? Or, put another way, do you believe that fewer LVEF reductions under 50% seen less often in SEQUOIA compared with EXPLORER would be sufficient to justify a pricing premium? Or would the safety benefit need to show up in the monitoring protocols or the label before there's any basis for a premium?
Robert Blum
executiveWell, to start, your question sort of assumes there will be a pricing premium, and we haven't addressed that; what we've said instead is that pricing would fall within a relatively similar ZIP code. That said, maybe I'll turn it over to Andrew, if he's willing, to speak to what we think will ultimately drive broader adoption for a next-in-class therapeutic in this category.
Andrew Callos
executiveYes, so regarding pricing, I believe Robert already covered that, and I'm guessing your question is about U.S. pricing, since that's where we can actually determine the price ourselves. In the U.S., though, we'll be right around whatever the market's established price is. When it comes to how payers take it up based on price, we're definitely going to be working—and already have been working—with commercial payers. We're pursuing medical exception through Medicare payers. I think we talked about the IRA challenges, which are an industry-wide issue, not something specific to us. That's how we'll secure access that we expect will be at parity with the competition, so we've essentially been removing that from the equation and concentrating on education, promotion, and uptake, along with patient support.
Robert Blum
executiveOur market research highlights how crucial risk reduction is, and in the end how that might hopefully lead to additional physicians prescribing a cardiac myosin inhibitor to more patients. And should approval come, our hope is that aficamten may come with a risk mitigation profile aligned with next-in-class goals.
Sean McCutcheon
analystregarding CK-586, could you discuss what you learned from the EMBARK findings? In your view, how are the target patients in AMBER meaningfully alike or unlike those in EMBARK? And assuming the mechanism is validated in the subsegment of HFpEF patients, which pharmacologic properties would you consider the most valuable?
Robert Blum
executiveRobert I. Blum, answer: Certainly. That's a solid question — perhaps Stuart is the right person to take that one, and Fady, if he'd like to contribute anything.
Stuart Kupfer
executiveAbsolutely, and I appreciate you asking that. To begin with, the possibility for benefit in this group has us quite optimistic, and that's largely because of what we saw with aficamten in nonobstructive HCM. Similar findings also showed up with mavacamten in nonobstructive HCM when it came to pharmacodynamic gains and symptom improvement. That said, what we've seen from EMBARK does give us reason to feel good about what CK-586 might do for these HFpEF patients who have hypercontractility. Of course, the population we're enriching has an ejection fraction of at least 60%. There's still a great deal for us to figure out regarding which dosing range could prove effective, safe, and tolerable. This initial inpatient study, then, should let us better define the pharmacodynamic advantages. We'll be tracking cardiac biomarkers including NT-proBNP and cardiac troponin, and naturally we'll also assess ejection fraction. One thing that struck us as quite favorable in our Phase I study was how shallow the exposure response profile looked, meaning only modest stepwise reductions in ejection fraction as CK-586 doses went up. I won't spend time speculating about comparing study designs or what EMBARK showed, but everything gathered to this point has us feeling very positive about CK-586, and about aficamten too, in nonobstructive HCM. So we're pretty hopeful and eager for this Phase II trial.
Robert Blum
executiveSince EMBARK didn’t involve a big patient population, we still have much to gain by evaluating a cardiac myosin inhibitor in a trial that enrolls more people and runs for a longer period. That’s why we intend to carry out a full development effort for CK-586, with the aim of generating useful information about CK-586.
Stuart Kupfer
executiveLet me just jump in here — apologies, Robert — I want to make one more point, which is that this study uses a placebo control. Because of that, the evaluation of the cardiac myosin inhibitor in this group of patients who have HFpEF along with hypercontractility is going to be considerably more rigorous than what we saw with EMBARK.
Robert Blum
executiveYeah. Thanks, Stuart.
Paul Choi
analystI'd like to go back to MAPLE for a moment, specifically around whatever clinical efficacy threshold might have come up in conversations with payers as they consider possible updates to guidelines. And has any input come back to you from them, or any commentary from the physician community, about what would count as clinically meaningful in this setting compared with metoprolol in order to prompt those guideline changes?
Robert Blum
executiveYeah. So I'm going to hand it to Andrew for his thoughts, though I believe it's too early for us to be discussing MAPLE with payers prior to having MAPLE data and prior to having any approval, which could potentially rest on SEQUOIA. That said, we are collecting insights regarding the way payers view these matters more broadly; so Andrew, perhaps you could weigh in, please?
Andrew Callos
executiveAbsolutely. So, like Robert said, what we're concentrating on with payers at this point centers on SEQUOIA. From a strategic standpoint, we're looking at ways you would begin incorporating MAPLE into discussions with payers, along with the value propositions, in both the U.S. and Europe. From a physician's perspective, MAPLE's value truly accomplishes 2 things. It grows the physician base. A portion of physicians tend to be less enthusiastic about using newer agents and are fine sticking with beta blockers as they are, since they lack real familiarity with CMI. So if you present a head-to-head against their current treatment, that definitely brings in more physicians; therefore it widens the market. And then regarding preference share, if you have a secondary study producing results in the ballpark of what we anticipate, that serves as a kind of confirmation for the primary study, which in turn boosts share further. So it ought to align with — from a guidelines standpoint, it ought to align with market growth, it should support share preference, and it will definitely support value propositions in the U.S. and Europe. However, right now we aren't discussing MAPLE with payers.
Jason Butler
analystOne brief question regarding 089. Your team has a lengthy background with this particular class. At a broad level, could you explain what sets 089 apart from the earlier candidates?
Robert Blum
executiveSure. 089 is derived from a completely distinct chemical scaffold, and on that point I'll turn it over to Fady shortly; however, it's important to recognize that our interest in 089 reflects lessons we've absorbed, and specifically, you'll learn more shortly regarding our forward development strategy, which emphasizes that development of 089 will not proceed in ALS, but instead in a muscular dystrophy—indeed, an uncommon disease form where we believe it might have a potential function. Fady, would you like to address how it could vary from previous fast skeletal compounds?
Fady Malik
executiveRight, so CK-089 is the third compound, and with every round of work we've landed on something more potent that also has improved pharmaceutical characteristics. This is a tough target, and our view is that 089 more or less gets the most efficacy we're able to extract from this mechanism of action, at minimum in preclinical models, and its physical properties make it a better fit for dosing and dose ranging and that sort of thing. So it's still early. We've got some quite interesting and encouraging preclinical data, and we'll be watching to see whether we can carry that forward into the clinic.
Robert Blum
executiveSince the time we were developing 2 earlier compounds, quite a lot has changed around skeletal muscle. We're also drawing on what those efforts taught us regarding how skeletal muscle force, power, endurance, fatigue and muscle function should be approached. And our belief is that CK-089 can carve out a position in which certain other players have been creating shareholder value. Once more, as we move ahead into Phase I and, we hope, past it, you'll be hearing more about what we have planned.
Charles Duncan
analystZia here, filling in for Charles. We’ve got just one question, and it’s about omecamtiv mecarbil. With COMET-HF about to begin, how do you see its standing in the heart failure space, especially while other therapies for heart failure with reduced ejection fraction keep advancing?
Robert Blum
executiveThanks. That’s a great question. I believe it deserves input from Fady and Stuart, and Andrew might also have a view on it, so I’ll invite our team to weigh in. Fady, let’s start with you.
Fady Malik
executiveSure. In the group we're intending to research with omecamtiv mecarbil—those suffering from severely reduced ejection fraction along with truly severe heart failure—a handful of fresh choices exist. A lot of the medications being created bring blood pressure down. Using them with these individuals can be difficult since they affect kidney function; plus they fail to tackle the fundamental reason these individuals are so symptomatic at this stage of their disease, namely that their cardiac function has declined considerably and is now severely reduced. So omecamtiv, I'd say, holds a rather distinctive role when it comes to being employed in this space, and it's simple in concept to grasp why it would help these individuals, simple to tell patients why you'd prescribe it. Thus, the excitement we've encountered when we made known the start of this trial—or rather made known the plan to run COMET within the heart failure community—has been fairly substantial. Honestly, I receive emails every week from investigators eager to take part, who feel thankful that we're pressing ahead with developing omecamtiv mecarbil, since it genuinely addresses an unmet need for them regarding what to try next once the foundational heart failure treatments stop working.
Robert Blum
executiveStuart, is there anything you'd like to contribute from the clinical side prior to us turning to Andrew for his commercial remarks?
Stuart Kupfer
executiveTo build on what Fady mentioned, these individuals are exhausting their available treatments. When you examine the risk profile for this group, a clear turning point appears right at the boundary of < > 30% ejection fraction. Once ejection fraction drops below 30%, the likelihood of death and acute decompensated heart failure rises sharply. As Fady noted, these people are running out of choices; they genuinely lack alternatives as guideline-directed medical therapy is withdrawn and they progress toward end-stage heart failure. Furthermore, what we saw in GALACTIC-HF was that this group not only faced the greatest danger of major heart failure events and mortality, but it was also the one where omecamtiv mecarbil delivered the greatest benefit. So there is a kind of fortunate convergence at play, and we believe this is a group that could genuinely gain from omecamtiv mecarbil.
Robert Blum
executiveThanks, Stuart. Andrew?
Andrew Callos
executiveAbsolutely. Looking at how we're positioned in the market, there are a few things to weigh. First, considering both the competitive landscape we might face down the road and what's currently available, plus guideline-directed medical therapy — that quad therapy approach — we anticipate it will be entirely generic by then. We're also examining pipeline products. So our confidence is high regarding a very distinct positioning for omecamtiv mecarbil, particularly given the clinical points just outlined. This group of patients also struggles with low blood pressure, kidney issues, or elevated potassium, and we expect omecamtiv to maintain a neutral profile regarding those adverse effects tied to guideline-directed treatment. There's also a solid health economic case. With few therapeutic choices available, we anticipate premium pricing, and because this sits atop our current specialty cardiovascular franchise — our field team, our headquarters staff — there's minimal incremental cost; so a very compelling economic rationale, a very compelling business rationale, a very compelling clinical rationale, along with assessing the future competitive landscape from a positioning standpoint. That's the reason we're advancing omecamtiv commercially.
Analyst
analystThat is very logical...
Robert Blum
executiveI am genuinely happy — absolutely, I simply wish to say something, it truly pleases me that a growing number of investors plus equity research analysts are asking us about the plan we have for omecamtiv mecarbil and that they are putting in the effort to study it. What I would put forward is that here lies a chance to capture the sorts of synergies that we have discussed regarding our specialty cardiology model, and anyone would be wrong to assume we are going after a patient group that already has solid options, since those really do not exist. Furthermore, we hold the view that omecamtiv mecarbil has both a positioning and a profile which, should this confirmatory study read out positive, could turn into a substantial opportunity. Therefore I look forward to bringing you further updates — and additional details on all of this. Operator, let's take the next question, please.
Srikripa Devarakonda
analystI also have a question about MAPLE. Fady, I believe you discussed obtaining imaging data in MAPLE that could point toward a distinction in cardiac remodeling. I'm curious whether 6 months — do you consider 6 months sufficient to show that distinction? I think you said it represents the beginning of demonstrating the distinction. And do you believe long-term data from FOREST would contribute to that? Or would longer data from MAPLE be necessary?
Fady Malik
executiveLet me phrase it another way, somewhat differently. With SEQUOIA, for example, we've already shared data showing that at 6 months, you begin to observe changes regarding reduction of LV mass and left atrial size that indicate favorable alterations in cardiac structure. So 6 months is sufficient. Those changes might grow over time, meaning longer follow-up is required; but I believe what we'll observe and hope we'll observe with MAPLE is that when beta blockers are used, none of those changes appear across 6 months; so the process never even begins. It doesn't — it doesn't get started. There's essentially no mechanistic basis to expect that you would observe it in those patients. And therefore if it hasn't begun by 6 months, there's no basis to expect that substantially longer treatment with that specific modality would produce the same kinds of changes that we'll show over time with aficamten.
Srikripa Devarakonda
analystUnderstood. What I was really driving at is whether it would be beneficial on the reimbursement side that what you observe at 6 months isn't only exercise capacity but also cardiac remodeling.
Fady Malik
executiveAndrew, would you like to field that one? From a doctor's standpoint, I know — in fact, we had a call about exactly this just this morning together with our steering committee. Everyone there wants to know how to prove that using this mechanism of action sooner, at an earlier stage, might alter the trajectory of a patient's disease progression. So that question generates quite a bit of enthusiasm among physicians, though demonstrating it is tough, and payers could well see things otherwise. It's hard to predict, yet in the end I believe it's a question worth answering.
Andrew Callos
executiveAppreciate the question. Ultimately, I believe the more evidence we're able to bring to the table when making our case to payers, MAPLE definitely begins contributing to that case. SEQUOIA obviously contributes to that case as well. Having outcomes data matters. At present, then, our attention is on tying Peak VO2 to outcomes, and secondary measures such as New York Heart Class and KCCQ all land extremely well with payers. This addition to that should certainly strengthen that case. So we have not yet raised the topic with payers. But once again, I think extra evidence is always beneficial.
Mayank Mamtani
analystCongratulations on a solid third quarter. Now regarding the CK-586 HFpEF Phase II study, with its 12-week treatment window, what kind of functional improvement would you anticipate based on what REDWOOD showed in nHCM patients? Also, can you put numbers to anything beyond the proBNP data you're going to collect? Or do we simply need to hold off for the MYK-224 AURORA study readout early next year to learn what a good result looks like under placebo control? And on top of that, how do you see this comparing with the GLP-1 drugs that are being used more and more in HFpEF?
Fady Malik
executiveI'll begin. I want Stuart to weigh in, but I suppose I'll just note that in our nHCM trial in REDWOOD, that nHCM cohort, treatment lasted 10 weeks, and that appeared sufficient to observe meaningful biomarker signals along with some symptom improvement. So I believe in this case, we have an equivalent likelihood of observing that among these patients. This is primarily a dose-finding study. Once we reached the nonobstructive HCM cohort in REDWOOD, we already possessed a fairly solid understanding of doses. Yet I think, once more, the length of this study ought to let us gain a sense of how the drug affects patients' symptoms as well as other measures of cardiac function and structure. As for GLP-1 use, Stuart, would you like to say something about how we're approaching that in this population?
Stuart Kupfer
executiveI'm sorry, I didn't quite get the question, Fady; so...
Fady Malik
executiveSo I suppose Mayank's question was about the way GLP-1s are being utilized in HFpEF at this point? And how are we bringing that therapy change into our thinking, along with how we consider our plans as we move ahead?
Stuart Kupfer
executiveOkay, so our thinking here is that these represent distinct mechanisms of action. And there has been — some evidence exists showing a degree of benefit for GLP-1 receptor agonist in HFpEF. How much of that comes from weight reduction versus another possible mechanism isn't fully clear right now; but the key point, I believe, is that this population faces elevated risk of adverse cardiovascular outcomes. And what we have observed in — certainly among patients with HFrEF is that adding a new mechanism of action targeting different pathways produces incremental risk reduction for adverse heart failure outcomes. So we expect the same from the mechanism of action behind CK-586 cardiac myosin inhibition, again, similar to what has been seen thus far in patients with nonobstructive HCM. So nothing suggests these mechanisms can't be complementary; therefore we don't view it as competitive, but I think that answers your question.
Robert Blum
executiveStill, I'd say there's much worth recognizing regarding how heart failure spans a range, going from severely reduced EF all the way to supernormal EF. Also, my view is that the way we're positioning ourselves sets us apart. It would be a mistake to assume every drug, GLP-1s included, will perform the same way throughout that range.
Fady Malik
executiveRight. Keep in mind, GLP-1s get used in individuals who are obese. Not every person with HFpEF falls into that category. That means certain portions of the HFpEF population clearly won't benefit from GLP-1s, simply because they won't require substantial weight reduction, or losing a great deal of weight would work against them. The same holds for those whose ejection fraction is high, and in a similar way, we'll aim to exclude individuals dealing with metabolic syndrome along with obesity, as a way of isolating a phenotype we believe responds to this mechanism of action.
Robert Blum
executiveThanks. Operator, can we take the following question, please?
Yasmeen Rahimi
analystThis is really great — for the first time in 2 years, during the Q&A, nobody mentioned REMS. So that's good to see. And I won't be posing anything about it either. All right; so I'm going to — it feels quite good to be done discussing that topic; but I'd love to keep the conversation going regarding MAPLE. I think in the end, what we may need from you is some clarity on how large the obstructive market is that either fails a beta blocker or actually deteriorates while on a beta blocker? And what sort of cost analyses might you be able to assemble to help build the case, further down the road, for aficamten to be placed as first line? But if you could perhaps give us some education on how big that market would be should MAPLE demonstrate superiority, that would be much appreciated, and I'll get back in the queue.
Robert Blum
executiveThanks. Andrew, you've done solid work on market segmentation. Would you like to take that one?
Andrew Callos
executiveAbsolutely. That's a great question. From the standpoint of beta blockers — and to be clear, this isn't drawn from claims data or any big market research dataset — we do understand that roughly 25% of patients have a contraindication to beta blockers, based at least on what more than 100 physicians have shared with us, and perhaps somewhere between 80% and 90% deal with undesirable side effects. So it's definitely not a drug that people are eager to take, based on what we've been told. When we consider those who don't do well on beta blockers and the value discussion around that, I'd say our general view is that building a value case for a cheap generic is tough. The value case, I believe, needs to be raised to a different level. Things such as KCCQ, New York Heart Class, what genuinely alters outcomes the way Peak VO2 alters outcomes, hard outcomes, outcomes like hospitalization, death, and so on. If someone has a lower New York Heart Class or an improved Peak VO2, then without question they have better outcomes, steering clear of septal reduction therapy or surgery, and the comorbidities tied to HCM. So those are the types of value arguments we truly focus on putting forward. A beta blocker failure, in my view, won't really contribute on that front. Where it does contribute, as I mentioned before, is that it generates extra evidence. It generates evidence that challenges what constitutes standard of care for a lot of physicians and pushes them to reconsider therapy potentially; so it widens the market. Obviously it isn't a bigger population — it's still oHCM — but it represents a bigger market opportunity and, as a result, greater market penetration.
Robert Blum
executiveA large share of what's being asked right now, I believe, centers on MAPLE, and my read is that this shows many of the analysts are updating their models to figure out what MAPLE might do when it comes to unlocking the market for even wider adoption. I'm grateful for that, and I want to emphasize — as Andrew is noting — that it's the accumulated data that I believe forms a tipping point that could leave cardiologists who practice beyond centers of excellence feeling more at ease writing a prescription for aficamten should it win approval. In our view, that will matter enormously. So it feeds into how quickly the commercial launch moves; it feeds into what should be growth of the category past the point where it's perhaps currently confined to centers of excellence. We've discussed how concentrated the prescriber base is, and we genuinely believe MAPLE can deliver a significant impact by strengthening the evidence that backs the use of cardiac myosin inhibitors. And that, I think, is what will allow this innovation to spread more effectively across the broader marketplace. Operator, could we take the next question, please.
Rohan Mathur
analystRohan here, filling in for Leland Gershell. Regarding aficamten, when you consider what the current launch of a cardiac myosin inhibitor implies, which parts of the commercial effort do you figure the existing treatment could help set in motion — building awareness in the market, supporting adoption, and eventually securing payer coverage, assuming aficamten becomes available?
Robert Blum
executiveRight. We've invested considerable effort into understanding what a next-in-class prospect could deliver when it comes to expanding the category, reaching more patients, and getting cardiologists engaged who perhaps aren't prescribing a cardiac myosin inhibitor at this point. Much of that, in our view, ties back to what we've consistently described regarding a next-in-class profile. Safety and efficacy aren't the whole story. Ease of use and convenience matter; the patient experience matters. And perhaps, Andrew, you could elaborate a little on those points.
Andrew Callos
executiveOkay, so when you're coming in as the second agent, I believe we can — this is an illness where a novel treatment exists but no targeted therapy has been available. That's why we're running our own effort to build disease awareness. Not long ago we launched a campaign aimed at HCPs, and in early Q1 we did one with patients. I think a lot of people across the U.S. have come across direct-to-consumer TV ads for this category. Awareness of the disease is wider these days. Patient organizations are out there too, so between all of that, payers become aware. They encounter these efforts in the marketplace through physicians; it gets patients in doctors' offices discussing possibly other treatment choices; so greater awareness really ought to mean a bigger market opportunity for us, since we aren't struggling against lack of disease awareness. Our education focus shifts more toward aficamten, its distinctive properties, and the places where it stands apart.
Robert Blum
executiveI appreciate it. To everyone joining us on today's call, thank you for the ongoing backing and curiosity regarding Cytokinetics. Clearly, there's plenty on the agenda; it's been an extremely active 12 months. In terms of hitting our objectives, Q3 represented a solid period of advancement. Should you not have done so yet, I'd urge you to tune into the investor event archived on our site. We explored considerable specifics about our approaches, not only concerning aficamten and oHCM, but additionally nHCM and the way that forms a continuous thread toward our specialty cardiology franchise, grounded in omecamtiv as well as CK-586. What you picked up on today reflects not merely momentum across those initiatives, but likewise within research and earlier-stage development, and how all of it sits inside an organization that is exercising caution around deploying capital and pursuing efficiencies capable of generating commercial synergies. As I noted, our aim isn't merely to bring aficamten to market next year, but to accomplish that in a manner that stands apart and might allow us to prepare the groundwork for the franchise we've discussed. Once more, I'd like to express gratitude to each of you for your fascination with our efforts and your focus during this call. We're eager to continue updating you over the rest of the year. With that said, operator, let's wrap up the call, please.
Operator
operatorThanks. That brings us to the end of today’s conference call. We appreciate everyone joining us. You’re free to hang up now.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Cytokinetics, Incorporated transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Cytokinetics, Incorporated earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Cytokinetics, Incorporated or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.